R3i Editorials

R3i editorials, created by members of the R3i board, focus on addressing the persistent challenges of residual cardiovascular risk. These editorials serve to educate healthcare professionals about emerging insights and therapeutic strategies related to lipid-related risk factors, such as triglyceride-rich lipoproteins and lipoprotein(a).

Latest Editorial

September 2026
Lipoprotein(a) and residual cardiovascular risk: how to manage patients?
Prof. Peter Libby, Prof. Michel Hermans, Prof. Pierre Amarenco, Prof. Lale Tokgözoglu 

First reported 60 years ago, lipoprotein(a) [Lp(a)] is now recognised as an important contributor to residual cardiovascular risk. Extensive evidence demonstrates that Lp[a] concentration associates with cardiovascular risk continuously and independently of low-density lipoprotein cholesterol (LDL-C) (1,2). Lowering LDL-C does not mitigate this risk (2). Elevated Lp(a) is also prevalent, affecting about one in five people with atherosclerotic cardiovascular disease (3,4). Taken together, these findings underline the need for more widespread Lp(a) testing to identify patients at risk, aligning with clinical management guidelines which recommend Lp(a) testing at least once in all adults (5,6).

While current thinking challenges the concept of an Lp(a) threshold for cardiovascular risk, clinical practice requires some pragmatic guidance for risk-based management. Although there is no defined Lp(a) target, the European Atherosclerosis Society proposes Lp(a) cut-offs to either ‘rule out’ (<30 mg/dL or <75 nmol/L) or ‘rule-in’ (>50 mg/dL or >125 nmol/L) associated risk, with an interim zone (30–50 mg/dL or 75–125 nmol/l) to consider Lp(a)-attributable risk in the presence of other risk factors and in risk stratification (1). Current guidelines also state that an Lp(a) concentration >50 mg/dL (about >125 nmol/L) associates with increased cardiovascular risk (5,6). However, the use a single cut-off may not be broadly representative globally given that Lp(a) levels differ with ethnicity. In INTERASPIRE (International Action on Secondary Prevention through Intervention to Reduce Events) which included patients hospitalised with coronary heart disease, median Lp(a) was highest in Africa (62 nmol/L) and lowest in the Western Pacific (22 nmol/L) (3). Findings from the Lp(a)JAPAN study, this month’s Landmark study, further support the proposal to lower Lp(a)-associated risk thresholds in populations with lower Lp(a) concentration (7), which merits further study.

Testing alone, however, will not alleviate the burden of Lp(a)-associated cardiovascular risk. Clinicians also need to treat elevated Lp(a) more aggressively. This has been difficult with the lack of specific Lp(a)-lowering therapies. Lifestyle intervention, although effective in the context of global risk management, does not influence Lp(a) concentration (1). In terms of available treatments, statin treatment does not lower Lp(a) and may even increase levels (1). The PCSK9 inhibitors have shown modest benefit (8,9), although the magnitude of Lp(a) lowering may be inadequate in most patients with high levels.

 

Novel Lp(a)-targeted therapeutics are currently undergoing evaluation in major cardiovascular outcomes studies (10-12). Subject to proven evidence that lowering Lp(a) significantly reduces cardiovascular events, these treatments will change the landscape for clinical management of Lp(a)-associated residual cardiovascular risk. However, as was the case for the PCSK9 inhibitors, there are likely to be barriers to their use in clinical practice. Cost will be a major limiting factor, likely restricting use to patients with very high Lp(a) levels, consistent with patient inclusion criteria in the outcomes studies. These trials have set a very high bar for patient inclusion, ranging from >70 mg/dL or ∼>175 nmol/L for the antisense oligonucleotide pelacarsen (10), to up to 200 nmol/L for the siRNA therapeutics lepodisiran and olpasiran (11,12). However, data from INTERASPIRE show that about 50% of patients have elevated Lp(a) below these levels and therefore would not qualify for trial inclusion (3). This also holds true for populations with lower Lp(a) levels; in the Lp(a)JAPAN study approximately 50% of patients with elevated Lp(a), including those with well controlled LDL-C, had levels ≥30 and <50 mg/dL (≥75 and <125 nmol/L) (7). Thus, there is a high burden of patients with modestly elevated Lp(a) who would not be able to access these targeted therapies. For these patients, new evidence from a pooled trial analysis (13), discussed in this month’s Focus report, suggests that the cholesteryl ester transfer protein obicetrapib may represent an option, with the added benefits of efficacy in lowering LDL-C and apolipoprotein (apo) B, and the practical advantage of oral administration.  For the future,  muvalaplin, an oral small molecule which acts to inhibit the binding of apo(a) and apoB in the hepatocyte and disrupts the assembly of Lp(a), may offer another option, given its efficacy in lowering Lp(a) in an early trial (14) but has not yet entered phase III development.

Ultimately, we need to await the results of the ongoing major outcomes studies with specific Lp(a) lowering therapies, to best define the management of elevated Lp(a) to reduce residual cardiovascular risk.

References

  1. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement. Eur Heart J 2022;43:3925–46.
  2. Bhatia HS, Wandel S, Willeit P, et al. Independence of lipoprotein(a) and low-density lipoprotein cholesterol-mediated cardiovascular risk: a participant-level meta-analysis. Circulation 2025;151:312–21.
  3. Barkas F, Brandts J, De Bacquer D, et al. Global variation in lipoprotein(a) levels among patients with coronary heart disease: Insights from the INTERASPIRE Study and Implications for emerging Lp(a)-lowering therapies. J Am Coll Cardiol 2025;85:2028-42.
  4. Nissen SE, Wolski K, Cho L, et al. Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease. Open Heart 2022;9(2):e002060.
  5. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111-88.
  6. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2026:S0735-1097(25)10254-4.
  7. Kataoka Y, Ray KK, Nicholls SJ, et al. Lipoprotein(a) and residual cardiovascular risk in Japanese patients with coronary artery disease who achieve guideline-recommended low-density lipoprotein cholesterol goals. Eur Heart J 2026; doi.org/10.1093/eurheartj/ehag446.
  8. O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation 2019;139:1483–92.
  9. Szarek M, Bittner VA, Aylward P, et al. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J 2020;41:4245–55.
  10. Cho L, Nicholls SJ, Nordestgaard BG, et al. Design and rationale of Lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a). Am Heart J 2025;287:1–9.
  11. Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) – Outcomes Trial. (NCT05581303)
  12. A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events With Elevated Lipoprotein(a) – ACCLAIM-Lp(a). (NCT06292013).
  13. Nicholls SJ, Nelson AJ, Ray KK, et al. Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials. Eur Heart j 2026; doi.org/10.1093/eurheartj/ehag399.
  14. Nicholls SJ, Ni W, Rhodes GM, et al. Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial. JAMA 2025;333:222–31

Key words: Lipoprotein(a); testing; residual cardiovascular risk; specific Lp(a)-lowering therapy; pelacarsen; olpasiran; lepodisiran; obicetrapib; PCSK9 inhibitor